

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



New Ray Medicine  
新銳醫藥

## **New Ray Medicine International Holding Limited**

**新銳醫藥國際控股有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 6108)**

### **UPDATE ANNOUNCEMENT ON TRANSITIONAL ARRANGEMENTS RELATING TO AMENDMENT OF LISTING RULES**

Reference is made to the announcements of New Ray Medicine International Holding Limited (“**Company**”, together with its subsidiaries, referred to as the “**Group**”) dated 6 October 2017 and 12 January 2018 in relation to, among other matters, the letter dated 6 October 2017 issued by the Securities and Futures Commission of Hong Kong (“**SFC**”) to the Company and the suspension of trading in shares of the Company (“**Suspension**”), the announcements of the Company dated 25 May 2018, 4 June 2018, 1 August 2018, 1 November 2018, 1 February 2019, 2 May 2019, 2 August 2019 and 1 November 2019 in relation to the periodic update on the Suspension, as well as the announcement of the Company dated 30 July 2018 (“**Announcement**”) in relation to amendment of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) (“**Listing Rules**”) which has come into effect on 1 August 2018 (“**Effective Date**”).

The shares of the Company have been suspended from trading on 6 October 2017 pursuant to the direction of the SFC (“**Rule 8(1) Direction**”) under section 8(1) of the Securities and Futures (Stock Market Listing) Rules (Chapter 571V, the Laws of Hong Kong).

As set out in the Announcement, the Stock Exchange may cancel the Company’s listing under Rule 6.01A(2)(b)(i) of the Listing Rules if the Company fails to resume trading in its shares on or before 31 January 2020.

The Company would like to update its shareholders and potential investors that it has been informed by the Stock Exchange as follows:

- (i) after consultation with the SFC, the Stock Exchange will, until further notice, withhold exercising its right to delist the Company under Rule 6.01A(2)(b)(i) of the Listing Rules should trading in the Company's securities remain suspended on 31 January 2020;
- (ii) for the avoidance of doubt, this is without prejudice to the Stock Exchange exercising its right under Rule 6.01A of the Listing Rules at a later stage when the Stock Exchange considers appropriate;
- (iii) the Stock Exchange also reserves all its rights under the Listing Rules;
- (iv) the Company is reminded of its obligation to procure a resumption of trading as soon as possible; and
- (v) if the Stock Exchange is not satisfied that the Company has taken and is taking all reasonable steps to procure a resumption of trading, the Stock Exchange is likely to proceed to delist the Company without further delay.

#### **CONTINUED SUSPENSION OF TRADING**

Trading in the shares of the Company has been suspended with effect from 9:00 a.m. on 6 October 2017 by the Stock Exchange as directed by the SFC in accordance with Rule 8(1) Direction. Trading in the shares of the Company will remain suspended until further notice.

The Company reminds its shareholders and potential investors that they should refer to the announcements published on the respective websites of the Stock Exchange and the Company for any information relating to the Group.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

On behalf of the Board  
**New Ray Medicine International Holding Limited**  
**Liu Yang**  
*Chairman & Executive Director*

Hong Kong, 8 January 2020

*As of the date of this announcement, the executive Directors are Mr. Liu Yang, Mr. Huo Zhihong and Ms. Wang Qiuqin; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.*